Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from BioNxt Solutions ( (TSE:BNXT) ).
BioNxt Solutions has reported final results from a preclinical study in miniature pigs showing that its proprietary sublingual oral dissolvable film formulation of cladribine for multiple sclerosis achieved approximately 40% higher systemic drug exposure over 48 hours compared with a conventional oral tablet formulation. Using AUC (0–48 h) as the key pharmacokinetic measure, the sublingual film delivered a mean exposure of 39.46 ng·h/mL versus 28.11 ng·h/mL for tablets, supporting the efficiency of its transmucosal delivery approach and helping to de-risk advancement into human pharmacokinetic trials, with potential implications for dose optimization, improved tolerability and a more competitive positioning against existing MS treatments.
The most recent analyst rating on (TSE:BNXT) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on BioNxt Solutions stock, see the TSE:BNXT Stock Forecast page.
Spark’s Take on TSE:BNXT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BNXT is a Neutral.
The score is driven mainly by very weak financial performance (losses, negative equity, rising debt, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to assess given negative earnings and no dividend support, providing limited offset.
To see Spark’s full report on TSE:BNXT stock, click here.
More about BioNxt Solutions
BioNxt Solutions Inc. is a life sciences company focused on pharmaceutical drug reformulation and delivery technologies. The company is developing a proprietary needle-free, swallow-free sublingual oral dissolvable film platform aimed at improving systemic drug delivery for established therapies, with an initial focus on cladribine for the treatment of multiple sclerosis, a market currently served by high-selling oral tablet products such as Mavenclad.
Average Trading Volume: 80,280
Technical Sentiment Signal: Sell
Current Market Cap: C$57.25M
See more insights into BNXT stock on TipRanks’ Stock Analysis page.